Biosurgical Agents | Market Insights | Asia Pacific (Supplemental) | 2021
Following the negative short-term impact of the COVID-19 pandemic, the Asia Pacific biosurgical agent market will grow at a modest rate, driven by growing surgical procedure volumes due to expanding aging population and the rising prevalence of diseases associated with aging, obesity, diabetes, and cardiovascular disease, in addition to rising awareness of the clinical benefits of these products on surgical outcomes, and the introduction of new products with enhanced features and expanded indications. However, growing concerns over product cost and competition from local competitors will limit ASP growth in this market, thus hindering revenue expansion to some extent.
This Medtech 360 Report provides high-level market metrics for biosurgical agents in the Asia Pacific region, including country-level data for major countries and aggregate data for the rest of the Asia Pacific region, across a 10-year period.
